DTIL DTIL
Company Profile ↓Company Overview
DTIL (DTIL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 17.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $34.26M (-50.1% YoY); net profit $-45.72M.
- Trailing 12 Months Year-on-year growth — revenue -50.1%, earnings -738.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.80% |
| 1 Year: | -50.12% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -737.98% |
Stock Price Performance
| 1 Year: | +54.34% |
| 6 Months: | +92.53% |
| 3 Months: | +0.27% |
| 1 Month: | -19.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.53M | 1.87M | 2.54M | 5.46M | 5.39M | 4.87M | 7.00M | 1.08M | 7.36M | 16.35M | 68.81M | 24.04M | 3.32M | 3.82M | 7.36M | 8.78M | 19.79M | 13.12M | 17.58M | 49.90M | 576.00K | 29.00K | 18.00K | 13.00K | 10.84M |
| Operating Income | -9.23M | -12.12M | -10.45M | -19.49M | -23.87M | -21.98M | -27.50M | -32.81M | -26.04M | -18.74M | 21.63M | -11.54M | -27.34M | -29.55M | -14.68M | -13.35M | -3.13M | -12.36M | -4.19M | 24.15M | -21.27M | -22.11M | -21.88M | -20.67M | -9.07M |
| Net Income | -9.01M | -11.83M | -9.76M | -31.78M | -19.44M | -20.74M | -26.84M | -32.70M | -26.02M | -18.69M | 21.66M | -11.28M | -28.17M | -31.04M | -23.95M | -25.06M | -11.89M | -8.08M | 8.59M | 32.75M | -16.43M | -20.57M | -23.52M | -21.77M | -18.44M |
| Diluted EPS | - | - | - | - | - | - | - | -0.63 | - | - | 0.36 | -0.19 | -0.46 | -0.46 | -0.22 | -6.75 | -3.13 | -2.10 | 1.70 | 4.67 | -2.25 | -2.21 | -2.13 | -1.84 | -0.75 |
| R&D Expense | 8.12M | 10.87M | 9.74M | 19.96M | 22.76M | 19.79M | 24.88M | 25.18M | 24.87M | 25.59M | 37.23M | 25.94M | 19.97M | 22.94M | 11.76M | 11.05M | 13.09M | 15.85M | 13.34M | 17.23M | 13.08M | 13.59M | 12.77M | 13.35M | 13.11M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.88M | 22.24M | 24.29M | 115.53M | 25.10M | 48.73M | 68.70M | 34.26M |
| Operating Income | -47.91M | -87.20M | -109.83M | -39.38M | -62.31M | -43.74M | -26.16M | -52.15M |
| Net Income | -46.04M | -92.88M | -109.01M | -30.60M | -111.64M | -61.32M | 7.17M | -45.72M |
| Diluted EPS | - | - | - | -0.52 | -38.10 | -15.96 | 1.04 | -3.56 |
| R&D Expense | 45.12M | 82.42M | 98.06M | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 138.60M | 235.23M | 150.16M | 211.50M | 238.17M | 159.78M | 136.39M | 154.42M |
| Total Equity | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M | 92.25M |
| Cash & Equivalents | - | 103.19M | 180.89M | 89.80M | 143.66M | 189.58M | 116.68M | 85.90M | 110.82M |
| Long Term Debt | - | - | - | - | 2.48M | 22.22M | - | - | - |
| Total Liabilities | - | 98.64M | 96.92M | 105.73M | 120.33M | 177.74M | 140.92M | 80.00M | 62.17M |
| Current Liabilities | - | 14.07M | 26.93M | 42.83M | 35.98M | 59.66M | 49.99M | 14.98M | 8.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.72M | -71.02M | -87.39M | -10.85M | -45.75M | -84.11M | -58.45M | -65.84M |
| Investing Cash Flow | -15.66M | -24.67M | -5.03M | -5.80M | -3.32M | 5.83M | -215.00K | -634.00K |
| Financing Cash Flow | 107.78M | 173.37M | 1.33M | 70.52M | 94.98M | 5.39M | 50.45M | 95.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -440.2% | -392.1% | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Net Margin % | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
| ROE % | -115.2% | -67.1% | -245.4% | -33.6% | -184.7% | -325.1% | 12.7% | -49.6% |
| ROCE % | -38.5% | -41.9% | -102.3% | -22.4% | -34.9% | -39.8% | -21.5% | -35.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DTIL
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DURHAM, N.C., July 31, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ann…
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
DURHAM, N.C., July 27, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ann…
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 10, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ann…
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Genome Editing Market size & share revenue was valued at approximately USD 11.2 Billion in 2025 and is expecte…
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
DTIL — Frequently Asked Questions
What is the current share price of DTIL?
As of 2026-08-05 17:25 PDT, DTIL trades at $7.47 on NASDAQ/NYSE. Its 52-week range is $3.57 to $9.28.
What is the P/E ratio of DTIL?
DTIL trades at a trailing price-to-earnings (P/E) ratio of -2.10.
What is the return on equity (ROE) of DTIL?
DTIL has a return on equity (ROE) of -49.57%. Its return on capital employed (ROCE) is -35.84%.
Is DTIL a good stock to buy?
This page provides a data-driven analysis of DTIL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.